Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (RANIA)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02116660 |
Recruitment Status
:
Completed
First Posted
: April 17, 2014
Last Update Posted
: August 7, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: Raltegravir (MK-0518) Drug: Nevirapine Drug: Lamivudine Drug: Tenofovir Drug: Emtricitabine Drug: Lopinavir Drug: Ritonavir Drug: Atazanavir Drug: Darunavir | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02 |
Actual Study Start Date : | September 3, 2014 |
Actual Primary Completion Date : | July 10, 2017 |
Actual Study Completion Date : | July 10, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Raltegravir plus Nevirapine plus Lamivudine
Raltegravir 400 mg oral twice daily, plus nevirapine 200 mg oral once daily for 14 days followed by nevirapine 200 mg oral twice daily, plus lamivudine 150 mg oral twice daily for 96 weeks
|
Drug: Raltegravir (MK-0518)
Raltegravir (MK-0518) 400 mg tablets
Drug: Nevirapine
Nevirapine (NVP) 200 mg tablets
Drug: Lamivudine
Lamivudine (3TC) 150 mg tablets
|
Active Comparator: Protease Inhibitor/Ritonavir plus tenofovir/emtricitabine
Tenofovir/emtricitabine 300/200 mg oral once daily plus 1) lopinavir/ritonavir 400/100 mg oral twice daily or 800/200 mg oral once daily, or 2) atazanavir/ritonavir 300/100 mg oral once daily, or 3) darunavir/ritonavir 800/100 mg oral once daily or 600/100 mg oral twice daily
|
Drug: Tenofovir
Tenofovir disoproxil fumarate (TDF) 300 mg tablets
Drug: Emtricitabine
Emtricitabine (FTC) 200 mg tablets
Drug: Lopinavir
Lopinavir (LPV) 200 mg tablets
Drug: Ritonavir
Ritonavir (r) 100 mg tablets
Drug: Atazanavir
Atazanavir (ATV) 300 mg tablets
Drug: Darunavir
Darunavir (DAR) 400 mg tablets
|
- Change from Baseline in estimated Glomerular Filtration Rate (eGFR) [ Time Frame: Baseline and Week 48 ]
- Percentage of Participants with Suppressed Viremia (<50 copies/mL HIV-1 Ribonucleic Acid [RNA]) at Week 48 [ Time Frame: Week 48 ]
- Percentage of Participants with Suppressed Viremia (<50 copies/mL HIV-1 RNA) at Week 96 [ Time Frame: Week 96 ]
- Percentage of Participants with Decline in Renal Function at Week 48 [ Time Frame: Week 48 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male, or non-pregnant, non-breastfeeding female
- No previous history of virological failure
- No previous exposure to non-nucleoside reverse transcriptase inhibitors or integrase inhibitors
- No previous history of intolerance to lamivudine
- At least 2 documented plasma HIV-1 RNA <50 copies/mL and no HIV-1 >50 copies/mL in the 12 months before screening
- Receiving the same protease inhibitor/ritonavir plus tenofovir/emtricitabine combination for at least the 6 months before screening
- Has no major International Antiviral Society (IAS)-USA mutations on genotype testing performed before starting antiretroviral treatment
- Sexually-active participants and their partners of child-bearing potential agree to use a medically acceptable method of contraception from 2 weeks before Day 1 and for at least 6 months after the last dose of study drug (postmenopausal women are not required to use contraception; sexually-active male participants with a female partner of child-bearing potential must provide written informed consent to information regarding any pregnancy)
Exclusion Criteria:
- Positive for hepatitis B surface antigen (HBsAg+) or anticipated need for hepatitis C virus treatment
- Liver cirrhosis
- Has a history of diabetes mellitus, defined as initiation of antidiabetic treatment or verification of diabetes in a case report form
- Has any cancer, excluding stable Kaposi Sarcoma
- Allergy or sensitivity to the investigational product or excipients
- Female participant who is nursing
- Female participant who is pregnant or intends to become pregnant
- Has an active Acquired Immunodeficiency Syndrome (AIDS)-defining event except stable Kaposi Sarcoma or HIV Wasting Syndrome
- Received any investigational drug within 30 days before screening
- Participated in any other clinical trial within 30 days before signing informed consent for the current trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02116660
Study Director: | Medical Director | Merck Sharp & Dohme Corp. |
Responsible Party: | Merck Sharp & Dohme Corp. |
ClinicalTrials.gov Identifier: | NCT02116660 History of Changes |
Other Study ID Numbers: |
0518-284 2013-001637-40 ( EudraCT Number ) |
First Posted: | April 17, 2014 Key Record Dates |
Last Update Posted: | August 7, 2017 |
Last Verified: | August 2017 |
Additional relevant MeSH terms:
HIV Infections Renal Insufficiency Viremia Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Kidney Diseases Urologic Diseases Sepsis Systemic Inflammatory Response Syndrome |
Inflammation Pathologic Processes Ritonavir Lopinavir Darunavir Atazanavir Sulfate HIV Protease Inhibitors Tenofovir Lamivudine Raltegravir Potassium Emtricitabine Nevirapine Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |